NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

NCT06450041 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Universal Donor (UD) TGFβi NK Cells
DRUG: Temozolomide
DRUG: Irinotecan
DRUG: Dinutuximab
DRUG: GM-CSF

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Collaborators

Nationwide Children's Hospital
United Therapeutics
Children's Neuroblastoma Cancer Fund